ストックスクリーナーアプリを入手
0.2276
2.61%
-0.0061
AIM ImmunoTech Inc (AIM) 最新ニュース
AIM ImmunoTech highlights pancreatic cancer program momentum - scanx.trade
AIM Stock Soars 42% As Pancreatic Cancer Trial Hits Key Enrollment Milestone Before Schedule — CEO Sees 'Significant Value-Inflection Period' Ahead - Stocktwits
AIM ImmunoTech (AIM) Stock Forecast & Analyst Ratings - Moomoo
AIM Maintained by Ascendiant Capital -- Price Target Lowered to $7.00 - GuruFocus
AIM (AIM) Earnings Snapshot: EPS Does Not Reach the Reported Estimate in the Latest Reading; After Earnings: The Share Price Adds 1.84% in the Latest SessionHigh Estimate Range - vinanet.vn
Why Did AIM Stock Plummet 35% Today? - Stocktwits
AIM Q2 2026 Earnings: Wider-than-Expected Loss Prompts Investor CautionFinal Results - vinanet.vn
AIM ImmunoTech Inc (AIM) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
$AIM ImmunoTech (AIM.US)$ - Moomoo
Analysts’ Opinions Are Mixed on These Healthcare Stocks: AIM ImmunoTech (AIM) and Schrodinger (SDGR) - The Globe and Mail
Maxim Group Maintains AIM ImmunoTech(AIM.US) With Buy Rating, Maintains Target Price $1.5 - Moomoo
AIM ImmunoTech CEO Highlights Biodefense and Military Force Protection in Newly Published ‘Breaking Defense’ Article - The Manila Times
AIM's Ampligen-Treated Mouse Group Had 100% Ebola Survival - Stock Titan
Form 8K AIM ImmunoTech Inc For: 11 August By Investing.com - Investing.com Nigeria
Biodefense is force protection: Ready today, prepared for tomorrow - Breaking Defense
AIM ImmunoTech Releases Q2 2026 Financial Results - AlphaStreet
Form 8K AIM ImmunoTech Inc For: 10 August By Investing.com - Investing.com Australia
AIM ImmunoTech Q2 loss widens to $3.8M, EPS misses estimates - scanx.trade
AIM ImmunoTech Reports Completion of Phase 2 Ampligen Dosing in Metastatic Pancreatic Cancer Trial, Advances Phase 3 Planning - Quiver Quantitative
AIM ImmunoTech Reports Q2 2026: $9.9M Cash, $3.8M Net Loss - TradingView
AIM ImmunoTech Reports Second Quarter 2026 Financial Results and Highlights Significant Operational Execution Advancing Ampligen® Toward Planned Phase 3 Development in Pancreatic Cancer - The Manila Times
AIM Completes Pancreatic Cancer Study Dosing; Phase 3 Planned - Stock Titan
AIM ImmunoTech (NYSE: AIM) returns to positive equity after new financings - Stock Titan
AIM ImmunoTech Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
AIM ImmunoTech Inc (AIM) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Form 8K AIM ImmunoTech Inc For: 6 August By Investing.com - Investing.com Nigeria
AIM ImmunoTech signs $1.5 million manufacturing agreement with Sterling Pharma - Investing.com
AIM ImmunoTech (AIM) inks $1.5M manufacturing pact for Ampligen - Stock Titan
AIM ImmunoTech (AIM) Climbs 7.98% as Biotech Micro-Cap Tests Key Resistance at $0.29PCR Spike - dars.gov.et
AIM ImmunoTechDuripanc Overall Survival En - Moomoo
AIM ImmunoTech Ahead of Schedule on ‘Last Dose’ DURIPANC Critical Clinical Inflection Point - Yahoo Finance
AIM ImmunoTech Q1 2026 Earnings: Loss Widens 52.5% Past Estimates; Shares Rally 8.09%Analyst Coverage Count - dars.gov.et
AIM Q1 2026 Earnings: EPS Misses by 52.53% Yet Shares Rally 8.09%Earnings Recovery Stocks - vinanet.vn
AIM Q1 2026 Earnings: Wider-than-Expected Loss Misses Estimates; Shares Rise 8.09%EBITDA Analysis - Vinanet
AIM ImmunoTech Inc (AIM) Institutional Confidence - TradingKey
AIM ImmunoTech Inc (AIM) Cash Flow - TradingKey
AIM|AIM ImmunoTech Inc|Price:0.254|Chg%:+0.005 - TradingKey
AIM ImmunoTech Inc (AIM) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
AIM ImmunoTech Inc (AIM) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
AIM ImmunoTech Inc (AIM) Balance Sheet - TradingKey
AIM|AIM ImmunoTech Inc|Price:0.241|Chg%:-0.009 - TradingKey
AIM ImmunoTech Inc (AIM) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Aim Immunotech Inc. (AIM) Q2 2023 Earnings ReportResults, Call & Slides - TipRanks
Aim Immunotech Inc. (AIM) Q3 2023 Earnings ReportResults, Call & Slides - TipRanks
AIM ImmunoTech Inc. Revenue Breakdown – AMEX:AIM - TradingView
Zacks.com featured highlights include AIM ImmunoTech, Hasbro, Fox, Cencora and Intuitive Surgical - Yahoo Finance
AIM ImmunoTech Inc. (AIM) Stock Price, News, Quote & History - Yahoo! Finance Canada
AIM ImmunoTech Inc. (AIM) stock price, news, quote and history - Yahoo Finance Australia
AIM ImmunoTech Q1 2026 Earnings: EPS Misses Estimates as Company Continues Clinical DevelopmentForward Guidance Trends - vinanet.vn
0.86%
0.31%
大文字化:
|
ボリューム (24 時間):